JPRN-jRCT1052210010招募中4 期
COmparing New strategy Targeting aRrhythmogenic substrate Of Lasting-A trial Fibrillation Study - CONTROL-AF
Shizuta Sastoshi0 个研究点目标入组 80 人开始时间: 2021年4月22日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 21age old 至 <= 90age old（—）
- 性别
- All
入选标准
- •First time ablation procedure for persistent atrial fibrillation
- •Patients who can be followed for at least 1-year after procedure
- •Patients from who we get written informed consent
排除标准
- •Patients whose atrial fibrillation was restored after only pulmonay veins isolation
- •Patients who received ablation procedure or MAZ E procedure for for atrial fibrillation before enrollment
研究者
相似试验
招募中
不适用
The Randomized Controlled Trial Evaluating Utility of Catheter Ablation Us ing New Strategy Targeting Arrhythmogenic Substrate in Atrial Fibrillation Patients (CONTROL-AF)atrial fibrillationJPRN-UMIN000043392Kyoto University Hospital80
暂停
3 期
Non-inferiority study of a new therapeutic strategy for gout: immediate prescription of a hypouricemia treatment, febuxostat, compared to its deferred administration.
FEFACRIGOU2024-515547-34-00Centre Hospitalier Universitaire Rouen128
进行中（未招募）
1 期
on-inferiority study of a new therapeutic strategy for gout: immediate prescription of a hypouricemia treatment, febuxostat, compared to its deferred administration. FEFACRIGOThe goutMedDRA version: 21.0Level: LLTClassification code: 10003435Term: Articular gout Class: 10027433CTIS2024-515547-34-00Centre Hospitalier Universitaire Rouen128
招募中
不适用
Development of novel treatment strategy to prevent progression of arteriosclerosis in dialysis patientsend stage renal diseaseJPRN-UMIN000020384second department of internal medicine, Kansai Medical University Hirakata hospital100
进行中（未招募）
1 期
Evaluation d’une nouvelle stratégie thérapeutique chez des patients à fort risque évolutif, à la phase initiale de la sclérose en plaques : traitement séquentiel par mitoxantrone (Elsep 10mg/m² par mois pendant 6 mois) puis interféron bêta-1a (Rebif 44µg 3 fois par semaine) versus interféron bêta-1a seul. - 2MS1Sclérose en plaquesEUCTR2004-001601-10-FRCHRU Rennes266